期刊文献+

高效液相色谱法测定甲氨蝶呤对来氟米特在大鼠体内药动学的影响 被引量:4

原文传递
导出
摘要 目的:研究甲氨蝶呤对来氟米特在大鼠体内药动学的影响。方法:灌胃给予来氟米特以及灌胃给予甲氨蝶呤合并来氟米特,用HPLC法测定来氟米特代谢物A77 1726的药时曲线,使用DAS软件计算单独给药以及合并给药时来氟米特药动学参数。结果:口服来氟米特的血药经时过程符合一级吸收的二房室模型。单独给予来氟米特k10:4.368h-1,ka:0.501 h-1,k12:4.122 h-1,k21:0.241 h-1,AUC0-∞:12.638 mg.L-1 h-1,MRT0-∞:12.465 h,tmax:11 h,Cmax:1.422 mg.L-1;甲氨蝶呤合并来氟米特k10:0.219 1 h-1,ka:0.255 h-1,k12:0.156 h-1,k21:0.054 h-1,AUC0-∞:72.7 mg.L-1 h-1,MRT0-∞:24.139 h,tmax:4 h,Cmax:2.6 mg.L–1。结论:甲氨蝶呤能促进来氟米特的吸收,
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2012年第23期1929-1931,共3页 Chinese Journal of Hospital Pharmacy
基金 南京市卫生局医学科技发展重点项目(编号:ZKX08022) 南京市卫生局医学科技发展项目(编号:YKK11101)
  • 相关文献

参考文献10

  • 1Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis[J]. Nat Rev Drug Diseov, 2003, 2: 473-488.
  • 2Fox RI, Herrmann ML, Frangou CG, etal. Mechanism of ac- tion of leflunomide in rheumatoid arthritis[J]. Clin Immunol, 1999, 93(3): 198-208.
  • 3Sakellariou GT, Sayegh FE, Kapetanos GA, et al. Efficacy of leflunomide addition in relation to prognostic factors for pa tients with active early rheumatoid arthritis failing to metho-trexate in daily practice [J]. Ciin Rheumatol, 2012,31 (1) 163-167.
  • 4Kraan MC, Smeets TJM, van Loon MJ, et al. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis [J]. Ann Rheum Dis, 2004, 63: 1056- 1061.
  • 5Li WD, Ran GX, Teng HL, etal. Dynamic effcets of lefluno- mide on IL- 1, IL - 6 and TNF - alpha activity produced from periton calm acrophagesin adjuvant arthritis rats[J]. Acta Pharmacoi Sin, 2002, 23(8): 752 756.
  • 6Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Con- ference[J]. J Am Acad Dermatol, 2009, 60: 824-837.
  • 7彭磊,张茜,金涌,李俊.来氟米特活性代谢产物A771726在小鼠体内的药动学研究[J].安徽医药,2006,10(10):729-730. 被引量:5
  • 8Petra BG, Iztok G, BlaiR, et al. An investigation of the influ- ence o[ CYP1A2 and CYP2C19 Genetic polymorphism on 2- Cyano-3 hydroxy-N E 4-( trifluoromethyl ) phenyl 1-2 butenamide (A77 1726) pharmacokinetics in leflunomide-trea- ted patients with rheumatoid arthritis [J]. Drug Metabolism And Disposition, 2009 37:2061-2068.
  • 9Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?[J]. Curr Opin Rheumatol, 2011, 23(3): 288-292.
  • 10Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver en zyme tests among patients with rheumatoid arthritis or psoriat ic arthritis treated with rnethotrexate and/or leflunomide [J]. Ann Rheum Dis, 2010, 69(1): 43-47.

二级参考文献4

共引文献4

同被引文献34

  • 1冯长根,李琼.香青兰化学成分研究[J].中成药,2006,28(1):94-98. 被引量:44
  • 2张宁,毕方方,肖波,李玲,李国良,梁静慧,杨欢.慢性多发性肌炎临床及病理分析[J].中风与神经疾病杂志,2006,23(4):445-446. 被引量:3
  • 3彭磊,张茜,金涌,李俊.来氟米特活性代谢产物A771726在小鼠体内的药动学研究[J].安徽医药,2006,10(10):729-730. 被引量:5
  • 4Fenton BM, Lord EM, Paoni SF. Enhancement of tumor perfusionand oxygenation by carbogen and nicotinamide during single- andmultifraction irradiation. Radiat Res, 2000, 153( 1): 75-83.
  • 5Janssens GO, Rademakers SE, Terhaard CH, et al. Acceleratedradiotherapy with carbogen and nicotinamide for laryngeal cancer:results of a phase III randomized trial. J Clin Oncol, 2012, 30( 15):1777-1783.
  • 6Sharma PK, Dwarakanath BS, Varshney R. Radiosensitization by 2-deoxy-D-glucose and 6-aminonicotinamide involves activation ofredox sensitive ASKl-JNK/p38MAPK signaling in head and neckcancer cells. Free Radic Biol Med, 2012, 53(7): 1500-1513.
  • 7《化学药物非临床药代动力研究技术指导原则》课题研究组.化学药物非临床药代动力学研究技术指导原则.3版.北京:中国医药科技出版社,2005: 133-144.
  • 8钟南山.内科学[M].第7版.北京:人民卫生出版社,2009:72.
  • 9Patel V, IKukadiya H, Mashru R. Development of microemulsion for solubility enhancement of clopidogrel[J]. Iran J Pharm Res,2010,9(4) ,327-334.
  • 10王新春,邢建国,袁勇,等田蓟苷微乳组合物[P].ZL201210385134.1.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部